Evaluation of the XIENCE PRIME LL and XIENCE Nano Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders; Myocardial ischaemia; Stroke
Focus Registrational; Therapeutic Use
Acronyms EXPERT CTO
Sponsors Abbott Laboratories

13 Feb 2018 Status changed from active, no longer recruiting to completed.
02 Nov 2017 Results assessing long-term safety and efficacy of everolimus eluting stents (EES) for chronic total occlusion (CTO) revascularization, were presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
31 Mar 2014 Results after 1-year follow-up presented at the 63rd Annual Scientific Session of the American College of Cardiology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com